Fiche personne


Territoire

Champagne-Ardenne

Statut

Hospitalo-Universitaire

Publications


Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.

Osty M, Altwegg R, Serrero M, Benezech A, Lecomte A, Cadiot G, Vuitton L, Wampach A, Nancey S, Buisson A, le Berre C, Rouillon C, Gilletta C, Goutorbe F, Fumery M, Hammoudi N, Caillo L, Vidon M, Arab N, Sickersen G, Cavicchi M, Vieujean S, Charkaoui M, Richard N, Wils P, Caron B, Amiot A, Nuzzo A, Laharie D, Kirchgesner J, Uzzan M,

Aliment Pharmacol Ther. 2025 05 22;:

PErsistence and safety of subcutaneous infliximab 1 year after switch from intravenous route in IBD patients in REMission.

Mathieu N, Hupé M, Heluwaert F, Rivière P, Hébuterne X, Chupin A, Abitbol V, Bouguen G, Vuitton L, Gornet JM, Montuclard C, Nancey S, Cadiot G, Wils P, Gilletta C, de Maissin A, Altwegg R, Chanteloup E, Plastaras L, Ah Soune P, Bourreille A, Stefanescu C, Seksik P, Simon M, Uzzan M, Andrau P, Rouillon C, Arondel Y, Buisson A, Peyrin-Biroulet L, Mboup B, Vicaut E, Laharie D

Clin Gastroenterol Hepatol. 2025 05 19;:

Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study.

Megherbi I, Hoog C, Perrier M, Brixi H, Cadiot G, Hoeffel-Fornes C, Morland D

EJNMMI Res. 2025 05 6;15(1):53

Voir plus